Marie Kupjetz

Marie Kupjetz

Auto-generated profile, based on publicly available information

Marie Kupjetz

Research Group “Sports Medicine”, Institute for Sport and Sport Science TU Dortmund University Dortmund Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2024 in Brain Research
Verified
Journal Article
Open access
MKMarie Kupjetz
Marie Kupjetz
TCTiffany Y. Wences Chirino
Tiffany Y. Wences Chirino
NJNiklas Joisten
Niklas Joisten
PZPhilipp Zimmer
Philipp Zimmer
Cognitive impairment is a core symptom of multiple sclerosis (MS), resulting from inflammation-related brain damage and brain network dysfunction. Inflammation also causes dysregulation of the kynurenine pathway, which is the primary route of tryptophan metabolism. Kynurenine pathway dysregulation is characterised by a shift in concentrations of tryptophan catabolites, also referred to as kynurenines. Some kynurenines have neurotoxic effects that partly resemble the molecular mechanisms of MS pathophysiology underpinning brain damage and brain network dysfunction. The kynurenine pathway may therefore qualify as a mechanistic link between systemic inflammation, brain damage, and cognitive impairment in MS. This perspective article (1) provides an overview of inflammation-related kynurenine pathway dysregulation and MS-relevant neuroimmune properties of kynurenines and (2) summarises the current evidence on associations between systemic kynurenines, imaging metrics of brain structure or related markers, and cognitive performance in populations that present with kynurenine pathway dysregulation and are prone to cognitive impairment. These findings are used to (3) set a research agenda for future studies aimed at clarifying the role of the kynurenine pathway in brain damage and cognitive impairment in MS.

1 November 2025 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Closed access
MKMarie Kupjetz
Marie Kupjetz
MLMartin Langeskov-Christensen
Martin Langeskov-Christensen
MRMorten Riemenschneider
Morten Riemenschneider
SIStefan Inerle
Stefan Inerle
ULUwe Ligges
Uwe Ligges
PZPhilipp Zimmer
Philipp Zimmer
Kynurenine pathway (KP) metabolites modulate inflammatory activity and neuronal viability. The consequences of KP imbalance partly resemble the molecular mechanisms of multiple sclerosis (MS). An improved understanding of KP imbalance and its relevance in MS requires holistic approaches beyond single-metabolite investigations. Thus, we aimed to explore the presence of KP metabolite patterns in MS and to evaluate their relevance in relation to participant characteristics and clinical measures. In this multinational cross-sectional analysis, we determined serum concentrations of KP metabolites in persons with MS and healthy individuals using targeted metabolomics (LC-MS/MS). Analyses were conducted between March 24, 2022, and August 9, 2024. The source studies were conducted in Denmark, Germany, and Switzerland. All participants were aged 18 years or older and free of acute or chronic diseases besides MS. Persons with MS had mild to moderate disease severity (Expanded Disability Status Scale [EDSS] score ≤6.5). Following the investigation of individual metabolites, we explored KP metabolite patterns using exploratory factor analysis. Associations between KP metabolite patterns and participant characteristics, MS symptoms, and MRI metrics were investigated using correlation analyses, proportional odds regression, and multiple linear regression. The MS cohort included 353 participants (67.1% female) with a mean (SD) age of 46.1 (12.4) years. The mean (SD) EDSS score was 3.1 (1.8). The healthy control (HC) cohort included 111 participants (53.2% female) with a mean (SD) age of 45.7 (16.6) years. Persons with MS showed 2 distinct KP metabolite patterns: an inflammation-driven neurotoxic pattern (NeuroTox) and a neuroprotective pattern (NeuroPro). Greater NeuroTox was associated with a higher EDSS score, older age, and higher body fat percentage. Greater NeuroPro was associated with a lower EDSS score and higher cardiorespiratory fitness. Using a data-driven approach, we demonstrate the presence of 2 KP metabolite patterns, NeuroTox and NeuroPro, in MS. Greater NeuroTox and lower NeuroPro were both associated with greater disease severity. Future studies need to investigate the KP metabolite patterns across the MS disability spectrum and may use comparable approaches to investigate whether KP imbalance follows similar or disease-specific patterns in diseases other than MS. NCT03322761, NCT02661555, NCT04762342, NCT04356248, DRKS00017091, DRKS00031445, DRKS00028792, DRKS00029105.

28 January 2026 in Acta Physiologica
Verified
Journal Article
Open access
TCTiffany Y. Wences Chirino
Tiffany Y. Wences Chirino
FAFrederike Adammek
Frederike Adammek
SBSergen Belen
Sergen Belen
MWMatteo Winker
Matteo Winker
SPSebastian Proschinger
Sebastian Proschinger
PZPhilipp Zimmer
Philipp Zimmer
Aim: Indoles are tryptophan (Trp)‐derived metabolites that are produced by the gut microbiota and may influence the gut‐microbiota‐brain axis in multiple sclerosis (MS). Indole‐3‐lactate (ILA) is reduced in persons with MS and improves MS clinical scores in animal models via its anti‐inflammatory remyelinating properties. The ILA/indole‐3‐acetate (IAA) (ILA/AA) index is considered a neuroprotection index. Physical exercise and diet can modify gut microbiota and indole metabolism. Methods: This secondary analysis of a randomized control trial aimed to assess the effects of acute and chronic exercise on serum indoles in relapsing–remitting MS (RRMS). Thirty‐one RRMS patients (≥ 70% session attendance) completed a 10 week multimodal functional training (60 min, 3×/week) vs. a waitlist control group. Blood samples were collected at baseline and compared to a matched healthy control group, and after 10 weeks for the assessment of chronic effects. Additionally, acute effects of a single bout of exercise were assessed with a blood sample before, during, and immediately after one interim training session. Serum indole concentrations were measured using LC–MS/MS. Results: Baseline indole levels in RRMS patients differed from those of matched healthy controls, and reduced ILA levels were observed. The 10 week intervention increased the ILA/IAA index, while a single exercise bout induced an increase in both ILA and ILA/IAA. Conclusion: Multimodal functional training over 10 weeks led to an improved ILA/IAA index suggesting a neuroprotective shift in gut microbiota composition, and a single bout acutely increases the circulating level of ILA. Study registration number: DRKS00017091.

23 August 2025 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
FAFrederike Adammek
Frederike Adammek
WGWeronika Gralla
Weronika Gralla
MKMarie Kupjetz
Marie Kupjetz
ARAnnette Rademacher
Annette Rademacher
PZPhilipp Zimmer
Philipp Zimmer
NJNiklas Joisten
Niklas Joisten
Functional exercise training focuses on enhancing the body’s capacity for everyday movements by targeting a combination of strength, stability, balance, coordination, and flexibility. More flexible and less standardized exercise approaches, such as functional exercise training, may offer further benefits on improving symptoms in persons with MS (pwMS), but they have been less investigated. This review aims to provide a comprehensive overview of the existing literature on the effects of functional exercise training on functional outcomes (mobility, walking capacity, balance, and proprioception), physical (strength and endurance) and physiological performance measures, as well as patient-reported outcomes (Quality of Life, Fatigue) in pwMS. The systematic review was conducted according to the PRISMA guidelines. Literature searches were conducted in Medline (PubMed) and Cochrane CENTRAL (inception to 19th February 2025). We included studies investigating the effects of functional exercise training on any outcome in adult pwMS. The quality and reporting were evaluated using the Tool for the assEssment of Study qualiTy and reporting in EXercise (TESTEX). A total of 19 studies were included in the review, ranging from smaller pilot studies to larger randomized controlled trials. Interventions lasted between six and 16 weeks. Results of the studies included in this review were highly heterogeneous. Some of the included studies have demonstrated improvements in mobility, short and long walking capacity, balance, strength, and endurance measures as well as on quality of life and fatigue. Adherence to training was poorly reported. Functional exercise training for pwMS is a comprehensive approach to achieving functional improvements, strength gains, and improved endurance simultaneously, thereby promoting beneficial health effects. In future, a clear definition of functional exercise training is required, research should focus on the consistent reporting of treatment adherence, and investigate the long-term effects of functional exercise training in pwMS. PROSPERO registration number: CRD42023448077.

13 October 2026 in The FASEB Journal
Verified
Journal Article
Open access
MRMarcus Vinicius dos Santos Rangel
Marcus Vinicius dos Santos Rangel
GPGabriela Andrade Paz
Gabriela Andrade Paz
MSMaria das Graças Coelho de Souza
Maria das Graças Coelho de Souza
MKMarie Kupjetz
Marie Kupjetz
TCTiffany Y. Wences Chirino
Tiffany Y. Wences Chirino
JBJuliana Pereira Borges
Juliana Pereira Borges
Tryptophan (TRP) is primarily metabolized via the kynurenine (KYN) pathway, which plays a central role in energy homeostasis, as well as immune, inflammatory, and neurobiological regulation. Although a single exercise session may modulate this pathway, the magnitude and consistency of these responses remain unclear. Therefore, this meta‐analysis aimed to synthesize acute exercise–induced changes in KYN pathway metabolites. PubMed, Web of Science, and Scopus were searched from inception to June 2026. Clinical trials evaluating the effects of a single exercise session on circulating TRP and KYN pathway metabolites were included. Random‐effects meta‐analyses were performed using standardized mean differences (Hedges' g). Outcomes were analyzed separately for immediate post‐exercise responses (≤ 5 min) and recovery responses (> 5 min to 3 h). Prespecified subgroup analyses examined population characteristics, training status, and exercise modality. Of 3203 records, 24 clinical trials ( n = 695) were included in the systematic review, and 20 provided data for meta‐analysis. Immediately after exercise, TRP decreased, whereas KYN, KYN/TRP, kynurenic acid (KYNA), and quinolinic acid (QA) increased. During recovery, reductions in TRP and elevations in KYN/TRP persisted, whereas KYN and QA returned toward baseline. KYNA remained elevated, while QA/KYNA remained unchanged. Subgroup analyses suggested larger responses in healthy individuals, trained participants, and following aerobic exercise, particularly for TRP and KYNA. Exercise induces heterogeneous changes in KYN metabolism, characterized by reduced TRP and increased KYN/TRP ratio and downstream metabolites. These responses are transient and context‐dependent, reflecting acute changes in metabolic flux rather than sustained pathway remodeling. Trial Registration: PROSPERO, identifier CRD42022351481

29 July 2026 in Brain, Behavior, and Immunity
Verified
Journal Article
Open access
MKMarie Kupjetz
Marie Kupjetz
MLMartin Langeskov-Christensen
Martin Langeskov-Christensen
MRMorten Riemenschneider
Morten Riemenschneider
SIStefan Inerle
Stefan Inerle
ULUwe Ligges
Uwe Ligges
PZPhilipp Zimmer
Philipp Zimmer
Kynurenine pathway imbalance is a characteristic feature of multiple sclerosis (MS). Serum kynurenines contribute to latent factors reflecting a neurotoxic (NeuroTox) or neuroprotective pattern (NeuroPro). Previous single-metabolite studies show a favorable modulation of the kynurenine pathway by acute exercise, characterized by increased neuroprotective kynurenic acid. This study aims to investigate the acute and chronic effects of different exercise modalities on NeuroTox and NeuroPro. In this pooled analysis of randomized controlled trials, we followed four subcohorts of our previous work, in which we identified NeuroTox and NeuroPro. Serum concentrations of kynurenines were quantified by liquid chromatography-tandem mass spectrometry. Pattern stability was assessed by repeating exploratory factor analysis (EFA). Acute effects of a single session of combined strength-focused exercise (CE; FunTraiMS study) and chronic effects of exercise interventions, including CE (10 weeks; FunTraiMS study) and endurance exercise (3 weeks; HIITMS study and 24 weeks; EMSES and EXBRAIN studies), were evaluated using linear mixed-effects models. The four subcohorts included 273 participants (67.0% female; mean (SD) age: 44.5 (10.6) years). Repeated EFA resulted in similar factor loadings of serum kynurenines across subcohorts. CE induced an acute increase in NeuroPro (0.421, 95% CI [0.216, 0.626], p < 0.001) in FunTraiMS. Twenty-four-week endurance exercise induced a chronic decrease in NeuroTox (-0.432, 95% CI [-0.786, -0.080], p = 0.019) in EXBRAIN. NeuroTox and NeuroPro are temporally stable constructs. NeuroPro shows acute responsiveness to strength-focused exercise. NeuroTox may be chronically diminished by endurance exercise. Determinants and the clinical relevance of changes in NeuroTox and NeuroPro warrant further investigation.